Roche’s Bet On Next-Gen Sequencing Poses New Challenge For Illumina’s Market Dominance

With Sequencing By Expansion Technology A Year Away From Commercial Launch, Competition Takes Note As Of Now

Roche Diagnostics CEO Matthew Sause tells Medtech Insight about how the technology addresses the pricing challenges for mid- and low-throughput customers.

Gene editing tool
Roche’s new system is expected to be aggressively priced to undercut existing NGS providers (Shutterstock)

More from Device Area

More from Diagnostics